Osteoporosis in the aging male: Treatment options

Stephen P Tuck1, Harish K Datta21Departments of Rheumatology, James Cook University Hospital, Marton Road, Middlesbrough, Cleveland, UK; 2School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle, Newcastle upon Tyne, UKAbstract: In elderly women, loss in bone mass and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stephen P Tuck, Harish K Datta
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/bc22c6d1f88242038fc430a25bc665bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc22c6d1f88242038fc430a25bc665bc
record_format	dspace
spelling	oai:doaj.org-article:bc22c6d1f88242038fc430a25bc665bc2021-12-02T07:09:23ZOsteoporosis in the aging male: Treatment options1178-1998https://doaj.org/article/bc22c6d1f88242038fc430a25bc665bc2008-01-01T00:00:00Zhttps://www.dovepress.com/osteoporosis-in-the-aging-male-treatment-options-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Stephen P Tuck1, Harish K Datta21Departments of Rheumatology, James Cook University Hospital, Marton Road, Middlesbrough, Cleveland, UK; 2School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle, Newcastle upon Tyne, UKAbstract: In elderly women, loss in bone mass and micro-architectural changes are generally attributed to the onset of menopause. Men do not experience menopause, they do, however, experience age-related acceleration in bone loss and micro-architecture deterioration. The incidence of osteoporotic fractures in elderly men, just as in aged women, increases exponentially with age; the rise in men, however, is some 5–10 years later than in women. Up to 50% of male osteoporotics have no identifiable etiology; however elderly males have much higher likelihood of having an identifiable secondary cause than younger men. Therefore, clinical and laboratory evaluation of aged male osteoporotics must be thorough and should be aimed at identifying lifestyle or conditions contributing to bone loss and fragility. It is essential to identify and treat secondary causes and ensure adequate vitamin D and calcium intake before embarking upon treatment with pharmacological agents. The evidence from a limited number of trials suggests that bisphosphonates, especially alendronate and risedronate, are effective in improving BMD, and seem to be the treatments of choice in aged men with osteoporosis. In cases where bisphosphonates are contra-indicated or ineffective, teriparatide or alternatives such as strontium should be considered.Keywords: male osteoporosis, bone mineral density, fracture risk, bisphosphonates, PTHStephen P TuckHarish K DattaDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 521-536 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Stephen P Tuck Harish K Datta Osteoporosis in the aging male: Treatment options
description	Stephen P Tuck1, Harish K Datta21Departments of Rheumatology, James Cook University Hospital, Marton Road, Middlesbrough, Cleveland, UK; 2School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle, Newcastle upon Tyne, UKAbstract: In elderly women, loss in bone mass and micro-architectural changes are generally attributed to the onset of menopause. Men do not experience menopause, they do, however, experience age-related acceleration in bone loss and micro-architecture deterioration. The incidence of osteoporotic fractures in elderly men, just as in aged women, increases exponentially with age; the rise in men, however, is some 5–10 years later than in women. Up to 50% of male osteoporotics have no identifiable etiology; however elderly males have much higher likelihood of having an identifiable secondary cause than younger men. Therefore, clinical and laboratory evaluation of aged male osteoporotics must be thorough and should be aimed at identifying lifestyle or conditions contributing to bone loss and fragility. It is essential to identify and treat secondary causes and ensure adequate vitamin D and calcium intake before embarking upon treatment with pharmacological agents. The evidence from a limited number of trials suggests that bisphosphonates, especially alendronate and risedronate, are effective in improving BMD, and seem to be the treatments of choice in aged men with osteoporosis. In cases where bisphosphonates are contra-indicated or ineffective, teriparatide or alternatives such as strontium should be considered.Keywords: male osteoporosis, bone mineral density, fracture risk, bisphosphonates, PTH
format	article
author	Stephen P Tuck Harish K Datta
author_facet	Stephen P Tuck Harish K Datta
author_sort	Stephen P Tuck
title	Osteoporosis in the aging male: Treatment options
title_short	Osteoporosis in the aging male: Treatment options
title_full	Osteoporosis in the aging male: Treatment options
title_fullStr	Osteoporosis in the aging male: Treatment options
title_full_unstemmed	Osteoporosis in the aging male: Treatment options
title_sort	osteoporosis in the aging male: treatment options
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/bc22c6d1f88242038fc430a25bc665bc
work_keys_str_mv	AT stephenptuck osteoporosisintheagingmaletreatmentoptions AT harishkdatta osteoporosisintheagingmaletreatmentoptions
_version_	1718399597806616576

Osteoporosis in the aging male: Treatment options

Ejemplares similares